A Case of Mantle Cell Lymphoma Treated with Autologous Stem Cell Transplantation and Rituximab
So-Yeon OH; Moon-Ju JANG; Sei-Kyung CHANG; Doyeon OH; So-Young CHONG; So-Yeon OH; Moon-Ju JANG; Sei-Kyung CHANG; Doyeon OH; So-Young CHONG.
Korean Journal of Hematology
; : 215-219, 2006.
Artículo
en Ko
| WPRIM | ID: wpr-720717
Mantle cell lymphoma is a subtype of aggressive non-Hodgkin's lymphoma and usually presents in advanced stages. When treated with a regimen such as CHOP, the median survival is about three years. More aggressive front-line therapy with the hyper-CVAD regimen or high-dose therapy with stem cell support has shown encouraging results in several trials. The addition of rituximab to the chemotherapy regimens, or high-dose therapy, increased the response and survival rates in patients with mantle cell lymphoma. We report a case of mantle cell lymphoma that was successfully treated with aggressive front-line treatment strategies. The patient achieved complete remission with initial hyper-CVAD regimen, and was consolidated with autologous stem cell transplantation and subsequent rituximab.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados